title: JAK inhibition: the key to treating myeloproliferative neoplasm?
authors.forename: Raoul
authors.initials: R
authors.lastname: Tibes
authors.forename: James M
authors.initials: JM
authors.lastname: Bogenberger
authors.forename: Ruben A
authors.initials: RA
authors.lastname: Mesa
mesh_terms: D019046:Bone Marrow Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors* / Q000235:genetics; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D009570:Nitriles; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use; D011743:Pyrimidines; D011788:Quality of Life
chemical_list: D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; C507924:JAK2 protein, human; D053614:Janus Kinase 2